Youmanitarian 11 Jun 2021

Up next

Autoplay

Kerrville, Texas flooding update: Several confirmed dead as evacuations, rescue efforts continue alo

Youmanitarian · 24 Views

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

7 Views

TAKE ACTION

Donations would go to support charities for #HEALTHCARE / Ovarian Cancer

In #HEALTHCARE / Ovarian Cancer

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the KEYNOTE-100 trial (NCT02674061) of pembrolizumab in advanced recurrent ovarian cancer patients. Importantly, no significant difference in response rate was found between heavily and less heavily pretreated patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More ways to take action

Explore ways that you can help bring a solution to this issue.

Create Youms with
hashtags #HEALTHCARE

Create a challenge to
bring awareness to this issue for people to complete

Create a fundraiser to
support a charity that tackle this issue

Volunteer at charitable organization
that support this cause

Create a movement page dedicated to this cause to bring awareness.

Start a uCharity for this cause and invite people to join it to support this cause

Up next

Autoplay

Kerrville, Texas flooding update: Several confirmed dead as evacuations, rescue efforts continue alo

Youmanitarian · 24 Views

Please note that if you are under 18, you won't be able to access this site. Please note that this site may contain sensitive material and viewers discretion is advised.

Up next

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

Up next

Categories

Choose a payment method